Veloxis completes patient enrollment in LCP-Tacro 3002 pivotal Phase III trial Pharmaceutical Business Review The primary endpoint of the study is a composite endpoint, Biopsy Proven Acute Rejection, graft failure, loss to follow up or death and secondary endpoints include safety, tolerability and renal function assessments. Veloxis CEO and president Bill ... |
